Cargando…
Impact of hepatitis C oral therapy in portal hypertension
Chronic hepatitis C is a leading cause of morbidity and mortality, mainly related to fibrosis/cirrhosis and portal hypertension. Direct antiviral agents are highly effective and safe and can now cure > 90% of the patients. Sustained viral response (SVR) after interferon-based regimens has been as...
Autores principales: | Libânio, Diogo, Marinho, Rui Tato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514632/ https://www.ncbi.nlm.nih.gov/pubmed/28765688 http://dx.doi.org/10.3748/wjg.v23.i26.4669 |
Ejemplares similares
-
Hepatology in the COVID Era: Another C Virus, again Challenging the Liver
por: Peixe, Paula, et al.
Publicado: (2020) -
Portal Hypertension
por: Sun, Mingyu, et al.
Publicado: (2018) -
The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019) -
Impact of sustained virologic response in regression of portal hypertension in Egyptian patients with hepatitis C virus-associated cirrhosis and portal hypertension
por: Faheem, Heba Ahmed, et al.
Publicado: (2022) -
Management of Complications of Portal Hypertension
por: Vilela, Eduardo Garcia, et al.
Publicado: (2019)